drugset / Trial / NCT01685411
Busulfan and Cyclophosphamide Followed By ALLO BMT
NaSingle-groupOpen-labelTreatment
Summary
This is a treatment guideline to allow routine clinical data to be collected and maintained in Oncore (clinical database) and the University of Minnesota Blood and Marrow Database as part of the historical database maintained by the department.
Timeline
- Start
- 2013-01
- Primary completion
- 2020-02-10
- Completion
- 2020-02-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Busulfan | Small molecule | — | Intravenous |
| Subject | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Background | ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) | Protein / enzyme biologic | — | — |
| Background | Allopurinol | Small molecule | — | — |
| Background | Keppra | Unknown | — | — |
| Background | Mycophenolate Mofetil | Small molecule | 15 mg/kg | — |
| Background | Mycophenolate Mofetil | Small molecule | 3 g | — |
| Background | Tacrolimus | Small molecule | — | — |
| Background | filgrastim | Protein / enzyme biologic | 5 ug/kg | Intravenous |